img

Global Neuraminidase Inhibitors Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuraminidase Inhibitors Drug Market Insights, Forecast to 2034

Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.
Market Analysis and InsightsGlobal Neuraminidase Inhibitors Drug Market
Global Neuraminidase Inhibitors Drug market is expected to reach to US$ 983 million in 2024, with a positive growth of %, compared with US$ 928 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Neuraminidase Inhibitors Drug industry is evaluated to reach US$ 1386.5 million in 2029. The CAGR will be 5.9% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Neuraminidase Inhibitors Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Neuraminidase Inhibitors Drug market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Roche
GSK
Gilead Sciences
Daiichi Sankyo
AstraZeneca
Pfizer
Teva
Bristol-Myers Squibb
Sun Pharmaceutical
Segment by Type
Oseltamivir
Zanamivir
Peramivir
Laninamivir

Segment by Application


Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Neuraminidase Inhibitors Drug introduction, etc. Neuraminidase Inhibitors Drug Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Neuraminidase Inhibitors Drug
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Oseltamivir
1.2.3 Zanamivir
1.2.4 Peramivir
1.2.5 Laninamivir
1.3 Market by Application
1.3.1 Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuraminidase Inhibitors Drug Market Perspective (2018-2029)
2.2 Global Neuraminidase Inhibitors Drug Growth Trends by Region
2.2.1 Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Neuraminidase Inhibitors Drug Historic Market Size by Region (2018-2024)
2.2.3 Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029)
2.3 Neuraminidase Inhibitors Drug Market Dynamics
2.3.1 Neuraminidase Inhibitors Drug Industry Trends
2.3.2 Neuraminidase Inhibitors Drug Market Drivers
2.3.3 Neuraminidase Inhibitors Drug Market Challenges
2.3.4 Neuraminidase Inhibitors Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Neuraminidase Inhibitors Drug by Players
3.1.1 Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2024)
3.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2018-2024)
3.2 Global Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Neuraminidase Inhibitors Drug, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Neuraminidase Inhibitors Drug Market Concentration Ratio
3.4.1 Global Neuraminidase Inhibitors Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuraminidase Inhibitors Drug Revenue in 2022
3.5 Global Key Players of Neuraminidase Inhibitors Drug Head office and Area Served
3.6 Global Key Players of Neuraminidase Inhibitors Drug, Product and Application
3.7 Global Key Players of Neuraminidase Inhibitors Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuraminidase Inhibitors Drug Breakdown Data by Type
4.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Type (2018-2024)
4.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029)
5 Neuraminidase Inhibitors Drug Breakdown Data by Application
5.1 Global Neuraminidase Inhibitors Drug Historic Market Size by Application (2018-2024)
5.2 Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Neuraminidase Inhibitors Drug Market Size (2018-2029)
6.2 North America Neuraminidase Inhibitors Drug Market Size by Type
6.2.1 North America Neuraminidase Inhibitors Drug Market Size by Type (2018-2024)
6.2.2 North America Neuraminidase Inhibitors Drug Market Size by Type (2024-2029)
6.2.3 North America Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
6.3 North America Neuraminidase Inhibitors Drug Market Size by Application
6.3.1 North America Neuraminidase Inhibitors Drug Market Size by Application (2018-2024)
6.3.2 North America Neuraminidase Inhibitors Drug Market Size by Application (2024-2029)
6.3.3 North America Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
6.4 North America Neuraminidase Inhibitors Drug Market Size by Country
6.4.1 North America Neuraminidase Inhibitors Drug Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024)
6.4.3 North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Neuraminidase Inhibitors Drug Market Size (2018-2029)
7.2 Europe Neuraminidase Inhibitors Drug Market Size by Type
7.2.1 Europe Neuraminidase Inhibitors Drug Market Size by Type (2018-2024)
7.2.2 Europe Neuraminidase Inhibitors Drug Market Size by Type (2024-2029)
7.2.3 Europe Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
7.3 Europe Neuraminidase Inhibitors Drug Market Size by Application
7.3.1 Europe Neuraminidase Inhibitors Drug Market Size by Application (2018-2024)
7.3.2 Europe Neuraminidase Inhibitors Drug Market Size by Application (2024-2029)
7.3.3 Europe Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
7.4 Europe Neuraminidase Inhibitors Drug Market Size by Country
7.4.1 Europe Neuraminidase Inhibitors Drug Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2024)
7.4.3 Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Neuraminidase Inhibitors Drug Market Size (2018-2029)
8.2 China Neuraminidase Inhibitors Drug Market Size by Type
8.2.1 China Neuraminidase Inhibitors Drug Market Size by Type (2018-2024)
8.2.2 China Neuraminidase Inhibitors Drug Market Size by Type (2024-2029)
8.2.3 China Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
8.3 China Neuraminidase Inhibitors Drug Market Size by Application
8.3.1 China Neuraminidase Inhibitors Drug Market Size by Application (2018-2024)
8.3.2 China Neuraminidase Inhibitors Drug Market Size by Application (2024-2029)
8.3.3 China Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Neuraminidase Inhibitors Drug Market Size (2018-2029)
9.2 Asia Neuraminidase Inhibitors Drug Market Size by Type
9.2.1 Asia Neuraminidase Inhibitors Drug Market Size by Type (2018-2024)
9.2.2 Asia Neuraminidase Inhibitors Drug Market Size by Type (2024-2029)
9.2.3 Asia Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
9.3 Asia Neuraminidase Inhibitors Drug Market Size by Application
9.3.1 Asia Neuraminidase Inhibitors Drug Market Size by Application (2018-2024)
9.3.2 Asia Neuraminidase Inhibitors Drug Market Size by Application (2024-2029)
9.3.3 Asia Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
9.4 Asia Neuraminidase Inhibitors Drug Market Size by Region
9.4.1 Asia Neuraminidase Inhibitors Drug Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Neuraminidase Inhibitors Drug Market Size by Region (2018-2024)
9.4.3 Asia Neuraminidase Inhibitors Drug Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Type
10.2.1 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Application
10.3.1 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country
10.4.1 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neuraminidase Inhibitors Drug Introduction
11.1.4 Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.1.5 Roche Recent Developments
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Neuraminidase Inhibitors Drug Introduction
11.2.4 GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.2.5 GSK Recent Developments
11.3 Gilead Sciences
11.3.1 Gilead Sciences Company Details
11.3.2 Gilead Sciences Business Overview
11.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Introduction
11.3.4 Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.3.5 Gilead Sciences Recent Developments
11.4 Daiichi Sankyo
11.4.1 Daiichi Sankyo Company Details
11.4.2 Daiichi Sankyo Business Overview
11.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Introduction
11.4.4 Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.4.5 Daiichi Sankyo Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Neuraminidase Inhibitors Drug Introduction
11.5.4 AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.5.5 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Neuraminidase Inhibitors Drug Introduction
11.6.4 Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.6.5 Pfizer Recent Developments
11.7 Teva
11.7.1 Teva Company Details
11.7.2 Teva Business Overview
11.7.3 Teva Neuraminidase Inhibitors Drug Introduction
11.7.4 Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.7.5 Teva Recent Developments
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Details
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Introduction
11.8.4 Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.8.5 Bristol-Myers Squibb Recent Developments
11.9 Sun Pharmaceutical
11.9.1 Sun Pharmaceutical Company Details
11.9.2 Sun Pharmaceutical Business Overview
11.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Introduction
11.9.4 Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2024)
11.9.5 Sun Pharmaceutical Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Oseltamivir
Table 3. Key Players of Zanamivir
Table 4. Key Players of Peramivir
Table 5. Key Players of Laninamivir
Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Neuraminidase Inhibitors Drug Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Neuraminidase Inhibitors Drug Market Share by Region (2018-2024)
Table 10. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Neuraminidase Inhibitors Drug Market Share by Region (2024-2029)
Table 12. Neuraminidase Inhibitors Drug Market Trends
Table 13. Neuraminidase Inhibitors Drug Market Drivers
Table 14. Neuraminidase Inhibitors Drug Market Challenges
Table 15. Neuraminidase Inhibitors Drug Market Restraints
Table 16. Global Neuraminidase Inhibitors Drug Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Neuraminidase Inhibitors Drug Revenue Share by Players (2018-2024)
Table 18. Global Top Neuraminidase Inhibitors Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 19. Global Neuraminidase Inhibitors Drug Industry Ranking 2021 VS 2022 VS 2024
Table 20. Global 5 Largest Players Market Share by Neuraminidase Inhibitors Drug Revenue (CR5 and HHI) & (2018-2024)
Table 21. Global Key Players of Neuraminidase Inhibitors Drug, Headquarters and Area Served
Table 22. Global Key Players of Neuraminidase Inhibitors Drug, Product and Application
Table 23. Global Key Players of Neuraminidase Inhibitors Drug, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2018-2024)
Table 27. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2024-2029)
Table 29. Global Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Neuraminidase Inhibitors Drug Revenue Share by Application (2018-2024)
Table 31. Global Neuraminidase Inhibitors Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Neuraminidase Inhibitors Drug Revenue Share by Application (2024-2029)
Table 33. North America Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 34. North America Neuraminidase Inhibitors Drug Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 36. North America Neuraminidase Inhibitors Drug Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Neuraminidase Inhibitors Drug Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 39. North America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 41. Europe Neuraminidase Inhibitors Drug Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 43. Europe Neuraminidase Inhibitors Drug Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Neuraminidase Inhibitors Drug Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 46. Europe Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 48. China Neuraminidase Inhibitors Drug Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 50. China Neuraminidase Inhibitors Drug Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 52. Asia Neuraminidase Inhibitors Drug Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 54. Asia Neuraminidase Inhibitors Drug Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Neuraminidase Inhibitors Drug Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Neuraminidase Inhibitors Drug Market Size by Region (2018-2024) & (US$ Million)
Table 57. Asia Neuraminidase Inhibitors Drug Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Type (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Application (2018-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country (2018-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size by Country (2024-2029) & (US$ Million)
Table 65. Roche Company Details
Table 66. Roche Business Overview
Table 67. Roche Neuraminidase Inhibitors Drug Product
Table 68. Roche Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 69. Roche Recent Developments
Table 70. GSK Company Details
Table 71. GSK Business Overview
Table 72. GSK Neuraminidase Inhibitors Drug Product
Table 73. GSK Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 74. GSK Recent Developments
Table 75. Gilead Sciences Company Details
Table 76. Gilead Sciences Business Overview
Table 77. Gilead Sciences Neuraminidase Inhibitors Drug Product
Table 78. Gilead Sciences Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 79. Gilead Sciences Recent Developments
Table 80. Daiichi Sankyo Company Details
Table 81. Daiichi Sankyo Business Overview
Table 82. Daiichi Sankyo Neuraminidase Inhibitors Drug Product
Table 83. Daiichi Sankyo Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 84. Daiichi Sankyo Recent Developments
Table 85. AstraZeneca Company Details
Table 86. AstraZeneca Business Overview
Table 87. AstraZeneca Neuraminidase Inhibitors Drug Product
Table 88. AstraZeneca Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 89. AstraZeneca Recent Developments
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Neuraminidase Inhibitors Drug Product
Table 93. Pfizer Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 94. Pfizer Recent Developments
Table 95. Teva Company Details
Table 96. Teva Business Overview
Table 97. Teva Neuraminidase Inhibitors Drug Product
Table 98. Teva Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 99. Teva Recent Developments
Table 100. Bristol-Myers Squibb Company Details
Table 101. Bristol-Myers Squibb Business Overview
Table 102. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product
Table 103. Bristol-Myers Squibb Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 104. Bristol-Myers Squibb Recent Developments
Table 105. Sun Pharmaceutical Company Details
Table 106. Sun Pharmaceutical Business Overview
Table 107. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product
Table 108. Sun Pharmaceutical Revenue in Neuraminidase Inhibitors Drug Business (2018-2024) & (US$ Million)
Table 109. Sun Pharmaceutical Recent Developments
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Neuraminidase Inhibitors Drug Market Share by Type: 2022 VS 2029
Figure 3. Oseltamivir Features
Figure 4. Zanamivir Features
Figure 5. Peramivir Features
Figure 6. Laninamivir Features
Figure 7. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Neuraminidase Inhibitors Drug Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Online Pharmacy Case Studies
Figure 12. Others Case Studies
Figure 13. Neuraminidase Inhibitors Drug Report Years Considered
Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Neuraminidase Inhibitors Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2022 VS 2029
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Players in 2022
Figure 18. Global Top Neuraminidase Inhibitors Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Neuraminidase Inhibitors Drug Revenue in 2022
Figure 20. North America Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
Figure 22. North America Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
Figure 23. North America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 24. United States Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Neuraminidase Inhibitors Drug Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
Figure 28. Europe Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
Figure 29. Europe Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 30. Germany Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Neuraminidase Inhibitors Drug Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
Figure 38. China Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
Figure 39. Asia Neuraminidase Inhibitors Drug Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
Figure 41. Asia Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
Figure 42. Asia Neuraminidase Inhibitors Drug Market Share by Region (2018-2029)
Figure 43. Japan Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Neuraminidase Inhibitors Drug Market Share by Country (2018-2029)
Figure 53. Brazil Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Neuraminidase Inhibitors Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Roche Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 60. GSK Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 61. Gilead Sciences Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 62. Daiichi Sankyo Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 63. AstraZeneca Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 64. Pfizer Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 65. Teva Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 66. Bristol-Myers Squibb Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 67. Sun Pharmaceutical Revenue Growth Rate in Neuraminidase Inhibitors Drug Business (2018-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries